PHILADELPHIA, PA â ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, today announced that its’ Innovation Lab will travel to the Drug Information Association (DIA) Annual Meeting to give clinical researchers access to advanced models for clinical trials and patient data collection. The Traveling Lab is an extension of ERT’s permanent, Boston-based Innovation Lab, where pharmaceutical researchers and technological leaders collaborate with ERT scientists and engineers to determine if diverse technologies like wearables and mHealth devices can enhance patient data collected during clinical trials. The objective of the Lab is to advance electronic patient data capture, increase efficiencies and deliver more comprehensive patient insight and engagement during clinical development. June 27-29 at the Philadelphia Convention Center DIA attendees can visit booth #509 to immerse themselves in new technology simulations and experience the realities of patients and clinicians who might use these technologies in future clinical trials. Some of the concepts available for demonstration in the Traveling Lab include:
“As a leader in innovative patient data capture methods, we recognize the value in collaboration when it comes to advancing clinical research processes,” said James Munz, Vice President, Innovation at ERT. “We are thrilled to work with so many pharmaceutical and technology experts who share our desire to advance clinical patient data collection and ultimately lead researchers to better clinical decisions during drug development.” For additional information on the Innovation Lab and the Traveling Lab schedule, visit
https://www.ert.com/innovation-lab
.
About ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process. ERT delivers widely deployed solutions in centralized Cardiac Safety, Respiratory, and electronic Clinical Outcome Assessments (eCOA) â which includes patient-, clinician-, observer- and performance-reported outcomes â and cloud-based analytics and performance metrics. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products. For more information see
www.ert.com
. Join ERT on
,
,
YouTube
and
.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.